Journal of Advanced Zoology

ISSN: 0253-7214

*Volume **44** Issue **S-5 Year 2023** Page **884:901***

Potential of Probiotic Recombinant Microbial Enzymes: Overview of Expression, Purification, Characterization and Its Application in Various Diseases

J Durga[1], K Rajaganapathy[2*], R Srinivasan[2], R Saravanan[2]

[1]*Anneo Biotech Pvt Ltd, 4, 1st Cross St, RA Puram, Trustpakkam, Raja Annamalai Puram, Chennai, Tamil Nadu 600028*

[2]*Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Selaiyur, Chennai 600073, Tamil Nadu, India.*

**Corresponding author's E-mail:* rajaganapathy.pharmacy@bharathuniv.ac.in

Article History

Received: 26 June 2023
Revised: 03 Sept 2023
Accepted: 16 Oct 2023

Abstract

Probiotics, beneficial bacteria with significant therapeutic potential, have gained attention for addressing a range of health issues, including gastrointestinal disorders, immune deficiencies, and mental health concerns. This article delves into the expression and purification of recombinant microbial enzymes to harness the therapeutic potential of probiotics. Probiotics offer promise in promoting overall well-being and preventing diseases through their ability to modulate immune responses and enhance gut health. They have proven effective in alleviating symptoms related to conditions like irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea. These live microorganisms, when administered in sufficient quantities, restore gut flora balance and modulate immune responses. By engineering probiotics to produce therapeutic enzymes that aid digestion or regulate gut microbiota, they can significantly contribute to digestive health and mitigate IBS and IBD symptoms. The expression and purification of recombinant microbial enzymes play a crucial role in enhancing probiotics' therapeutic capabilities, enabling tailored treatments for various health challenges. In summary, probiotics represent a promising frontier in therapeutic microbiology and biotechnology. Their multifaceted benefits, when combined with recombinant microbial enzyme expression and purification, hold immense potential for advancing the field of therapeutic probiotics and improving human health.

Keywords: *Probiotics, Beneficial Bacteria, Therapeutic Use, Enzymes, Inflammatory Bowel Disease*

1. Introduction

In the realm of microbiology and biotechnology, the quest for innovative therapeutics has led to the emergence of probiotics as a promising avenue for combating various diseases. Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. These beneficial bacteria have shown immense potential in treating conditions such as gastrointestinal disorders, immune system deficiencies, and even mental health issues (Plaza-Diaz, *et al.*, 2019).

However, harnessing the full potential of probiotics requires effective expression and purification of recombinant microbial enzymes. This crucial step ensures that these enzymes can be produced at high yields and purified for therapeutic applications. In this article, we will explore the intricate world of expressing and purifying recombinant microbial enzymes for the application of therapeutic probiotics (Solanki, *et al.*, 2021).

Probiotics

Probiotics, derived from the Greek words "pro" meaning "for" and "bios" meaning "life," are living microorganisms that, when consumed in adequate amounts, confer health benefits on the host. These beneficial bacteria have gained significant attention in recent years due to their potential therapeutic applications in promoting overall well-being and preventing diseases. Probiotics can be found naturally in certain foods or can be taken as supplements to restore or enhance the microbial balance within our bodies (Dermyshi, *et al.*, 2017). The major pathways for their mode of action have been depicted in Fig. 1.



Thirdly, probiotics should be capable of adhering to the intestinal epithelium and colonizing within the gut environment (Niazi Amraii, *et al.*, 2014).

The therapeutic potential of probiotics lies in their ability to modulate immune responses and improve gut health. Numerous studies have shown that probiotics can alleviate symptoms associated with gastrointestinal disorders such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea. Moreover, these remarkable microorganisms have been explored for their potential role in preventing allergies, enhancing nutrient absorption, supporting mental health through the gut-brain axis, boosting immune function, and even reducing the risk of certain cancers (Hemarajata, *et al.*, 2013).

While traditionally associated with dairy products like yogurt and fermented foods such as sauerkraut or kimchi, probiotics now come in various formulations including capsules, powders, chewable tablets, or liquids. Furthermore, strains of Lactobacillus, Bifidobacterium, Streptococcus, and other genera have been extensively studied for their potential health benefits. The probiotics market continues to expand, with increasing research and development efforts focusing on identifying new strains and optimizing delivery methods to maximize their potential impact (Soemarie, *et al.*, 2021)

Therapeutic Applications of Probiotics for Various Diseases

Probiotics have emerged as a promising field in the quest for novel therapeutic approaches for various diseases. Extensive research has shown their potential in managing conditions such as inflammatory bowel disease, irritable bowel syndrome, and even certain types of cancer. These live microorganisms, when administered in adequate amounts, exert beneficial effects on the host by restoring the balance of gut flora and modulating immune responses (Tegegne & Kebede, 2022). A list of potential probiotic micro-organisms having therapeutic properties has been provided in Table 1.

Table 1 Probiotic micro-organisms having therapeutic properties

S.No	Human Diseases	Probiotic microorganisms	References
1	Hypercholesterolemia	L. casei, L. plantarum, L. paracasei, Lc. lactis, Ent. faecium	Hlivak et al., 2005, Ayyash et al., 2018
2	Allergies	L. GG, L. rhamnosus GG	Licciardi et al., 2013, Goyal et al., 2012
3	Irritable bowel disease	Bif. lactis, L. acidophilus, L. casei, L. plantarum, Sac. cerevisiae	Basturk et al., 2016, Cayzeele-Decherf et al., 2017
4	Colon Cancer	Lactic acid bacteria (LAB)	(Uccello et al., 2012, Kahouli et al., 2013)
5	Diabetes and obesity	L. acidophilus NCFM, L. gasseri SBT2055, L. rhamnosus CGMCC1.3724	Andreasen et al., 2010, Kadooka et al., 2010

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, poses significant challenges in treatment. However, probiotics have shown promising results by reducing inflammation and alleviating symptoms associated with IBD. They do so by positively influencing the gut microbiota composition and enhancing the integrity of the intestinal barrier (Jonkers &Stockbrügger, 2003).

Irritable bowel syndrome (IBS) affects millions worldwide with its debilitating symptoms like abdominal pain, bloating, and altered bowel habits. Probiotics have been identified as a potential remedy for IBS due to their ability to modulate gut motility and reduce visceral hypersensitivity. By restoring a healthy microbial community within the gut, probiotics can alleviate symptoms and improve overall quality of life (Satish Kumar, *et al.*, 2022).

Emerging evidence suggests that probiotics may also play a role in preventing or even treating certain types of cancer. Notably, studies have indicated their potential to enhance immune responses against tumor cells while reducing inflammation within the body. Furthermore, probiotics can influence metabolic activities that affect carcinogenesis processes positively (Górska, *et al.*, 2019).

Recombinant Probiotics

Recombinant probiotics, a fascinating area of research in the field of biotechnology, involve the genetic modification of probiotic microorganisms to enhance their therapeutic potential. These modified microorganisms are engineered to produce specific proteins or enzymes that can be utilized for various therapeutic applications. Through the process of gene manipulation, recombinant probiotics offer the promise of delivering targeted treatments and improving human health (Singh, *et al.*, 2022).

The concept behind recombinant probiotics lies in harnessing the natural capabilities of beneficial bacteria and modifying them to express desired proteins or enzymes. This approach allows for the production and delivery of bioactive molecules with precise functions, such as antimicrobial peptides, enzymes involved in nutrient metabolism, or molecules that modulate immune responses. By introducing these recombinant organisms into the body, it becomes possible to target specific conditions or diseases (Romero-Luna, *et al.*, 2021).

One exciting aspect of recombinant probiotics is their potential use in treating gastrointestinal disorders. For example, by engineering these microorganisms to produce therapeutic enzymes that aid in digestion or modulate gut microbiota composition, they can play a significant role in promoting digestive health and alleviating symptoms associated with conditions like irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) (Behnsen, *et al.*, 2013)

In addition to gastrointestinal disorders, recombinant probiotics hold promise for applications in other areas as well. They have been explored for their potential therapeutic effects on respiratory infections, metabolic disorders like diabetes and obesity, immune-related diseases such as allergies and autoimmune disorders, as well as mental health conditions including anxiety and depression. The ability to genetically engineer probiotic microorganisms opens up a world of possibilities for targeted therapies across multiple fields of medicine (Kali, 2015).

Gut Microflora

Within the intricate ecosystem of the human gastrointestinal tract lies a mesmerizing world known as gut microflora. These communities of microorganisms, including bacteria, fungi, and viruses, play an integral role in maintaining our overall health and well-being. The gut microbiota consists of trillions of microorganisms that coexist harmoniously, forming a symbiotic relationship with our bodies (Thursby & Juge, 2017).

The diversity of the gut microbiota is astounding, with over 1,000 different species residing within each individual. This vast array of microbial inhabitants contributes to various essential functions such as aiding digestion, synthesizing vitamins, modulating the immune system, and even influencing mental health. The delicate balance between beneficial and harmful microbes is crucial for optimal gut functioning (Rowland, *et al.,* 2018).

An intriguing aspect of gut microflora is its adaptability to environmental changes and external influences such as diet or medication. Imbalances in this finely tuned ecosystem can lead to dysbiosis – a disruption in the normal composition of gut bacteria – which has been associated with a wide range of health issues including inflammatory bowel disease, obesity, allergies, and even mental disorders (Gagliardi, et al., 2018).

Fortunately, emerging research suggests that targeting these imbalances through therapeutic probiotics can offer promising solutions for restoring equilibrium within the gut microbiota. By introducing specific strains of beneficial bacteria into our digestive system through probiotic supplements or foods like yogurt or sauerkraut, we have the opportunity to positively influence our gut microflora and potentially mitigate certain health conditions (Wang, et al., 2021).

Flora Imbalance

Within the intricate ecosystem of our gastrointestinal tract resides a vast array of microorganisms, collectively known as the gut microbiota or flora. These microscopic inhabitants play a crucial role in maintaining our overall health and well-being. However, certain factors such as antibiotic usage, dietary changes, and stress can disturb the delicate balance of these microbial communities, leading to what is known as flora imbalance (Quigley, 2013).

A flora imbalance occurs when there is a disruption in the composition and diversity of the gut microbiota. This disturbance can have profound implications for our health, as these microorganisms are involved in vital functions such as digestion, immune regulation, and even mental well-being. The repercussions of flora imbalance can manifest in various ways, ranging from mild digestive discomfort to more severe conditions like inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) (Clapp, *et al.,* 2017).

The consequences of flora imbalance extend beyond merely physical symptoms; emerging research suggests a potential link between an imbalanced gut microbiota and mental health disorders such as anxiety and depression. This revelation highlights the intricate connection between our gut and brain known as the gut-brain axis. Restoring harmony to this delicate ecosystem becomes imperative not only for physical but also for mental health (Kumar, *et al.,* 2023).

Fortunately, innovative approaches utilizing recombinant microbial enzymes in therapeutic probiotics show promising potential for rebalancing the gut microbiota. By incorporating specific enzymes into probiotic formulations, scientists aim to modulate the composition of microbial communities within our gastrointestinal tract selectively. These engineered enzymes can assist in breaking down complex carbohydrates or enhancing nutrient absorption – ultimately promoting a healthier environment within our guts (Ezzamouri, *et al.,*2021).

Steps Required for Expressing Recombinant Protein Using Bacterial Expression System

Selection of Suitable Expression System

In order to successfully express recombinant proteins, it is paramount to choose an appropriate bacterial expression system. This involves considering factors such as protein complexity, solubility, and yield.

The choice between commonly used systems like E.coli, Bacillus subtilis, or Pseudomonas putida should be based on the specific requirements of the protein being expressed (Liu, *et al.*, 2013).

The selection process also entails evaluating the regulatory elements within each system, such as promoters and terminators. Optimal expression levels can be achieved by understanding how these elements interact with the recombinant DNA construct. A well-matched system ensures efficient translation of the target gene into functional protein (Horwitz, *et al.*, 2015).

In addition to regulatory elements, it is crucial to assess the compatibility between host strain and plasmid vectors carrying the recombinant DNA. Compatibility ensures successful propagation of plasmids during cell growth and maintenance of stability throughout fermentation processes (Shintani, *et al.*, 2015).

Cloning and Transformation

The next step involves cloning the target gene into a suitable vector for transformation into bacteria. This is typically accomplished by using restriction enzymes to digest both the vector and gene of interest, followed by ligation using DNA ligase. The resulting recombinant vector contains all necessary elements for expression: promoter, terminator, ribosome binding site (RBS), etc (Kago, *et al.*, 2023).

The transformed plasmids are then introduced into competent bacterial cells through various methods such as chemical treatment or electroporation. Successful transformation results in colonies containing cells harboring the recombinant plasmid which will express our desired enzyme (Sirajuddin, & Sundram, 2020).

To ensure proper verification and selection of transformants that have incorporated our target gene efficiently without any mutations or rearrangements, appropriate screening methods like colony PCR or DNA sequencing should be employed (Nouemssi, *et al.*, 2020).

Expression and Optimization

Following successful transformation, the recombinant bacterial cells are grown under controlled conditions to induce protein expression. The optimization process requires careful consideration of several parameters such as temperature, pH, inducer concentration, and fermentation time (Rosano, & Ceccarelli, 2014).

Monitoring the growth kinetics of the transformed cells allows for precise determination of the optimal induction time for maximum protein expression. This can be achieved by periodically sampling culture aliquots and analyzing protein levels using techniques like SDS-PAGE or Western blotting (Mahmood, & Yang, 2012).

Additionally, optimizing culture conditions may involve adjusting nutrient availability by varying carbon or nitrogen sources supplemented in the growth medium. The aim is to achieve high cell density and enhanced protein production while maintaining cell viability throughout the fermentation process (Singh, *et al.*, 2017).

Purification and Analysis

After successful expression and optimization, purification of the recombinant enzyme is necessary to obtain a pure and active form. Various purification techniques such as chromatography (affinity, ion exchange, size exclusion) can be employed depending on the properties of the target enzyme (Pina, *et al.*, 2014).

The purified enzyme is then subjected to detailed characterization using techniques such as enzymatic assays, mass spectrometry, circular dichroism spectroscopy, or X-ray crystallography if applicable. These analyses provide valuable information about enzymatic activity, structure-function relationships, stability under different conditions (Ferraro, *et al.*, 2021).

The final step involves thorough analysis of purified enzyme batches for quality control purposes before further downstream applications are pursued. This ensures that any potential contaminants or impurities are minimized to meet regulatory standards for therapeutic probiotic use or other desired applications (Fenster, *et al.*, 2019).

Various Methods and Types of Recombinant Protein Expression Techniques

Bacterial Expression Systems

Bacterial expression systems are widely used for the production of recombinant proteins due to their cost-effectiveness, simplicity, and high expression levels. The most commonly used host bacterium is Escherichia coli (E. coli), which offers a well-established genetic background and numerous expression vectors (Fakruddin, *et al.,* 2012).

One popular method is the induction of protein expression using a strong promoter such as T7 or lac, coupled with the addition of an inducer molecule like isopropyl β-D-1-thiogalactopyranoside (IPTG). This system allows for tight control over protein production (Briand, *et al.*, 2012).

In recent years, advancements in bacterial expression systems have led to the development of novel strategies like autoinduction media, which eliminate the need for manual induction by providing a gradual increase in nutrient availability to sustain protein expression over extended periods (Fan, *et al.,* 2021).

The use of bacterial expression systems not only allows for efficient production but also enables easy scale-up processes, making it an attractive choice for industrial applications in therapeutic probiotics development (Baral, *et al.,* 2021).

Yeast Expression Systems

Yeast expression systems, particularly Saccharomyces cerevisiae (S. cerevisiae), have emerged as powerful tools for recombinant protein production due to their eukaryotic nature and ability to carry out post-translational modifications necessary for proper folding and functionality of certain proteins (Vieira Gomes, *et al.,* 2018).

S. cerevisiae offers robust growth characteristics and efficient secretion machinery that facilitates high-level extracellular production of recombinant proteins. Additionally, its well-characterized genome provides precise genetic manipulation (Parapouli, et al., 2020).

A notable advantage of yeast expression systems is their compatibility with large-scale fermentation processes, enabling cost-effective production of therapeutic probiotics on an industrial scale. This scalability makes yeast expression systems particularly attractive for commercial applications (Baghban, *et al.*, 2019).

Furthermore, advancements in yeast engineering have allowed the development of specialized strains with enhanced protein folding and secretion capacities, further improving the yield and quality of recombinant proteins (Lin, *et al.,* 2023).

Insect Cell Expression Systems

Insect cell expression systems, employing baculovirus-mediated gene transfer into insect cells such as Spodoptera frugiperda (Sf9) or Trichoplusiani (High Five), offer numerous advantages for recombinant protein production (Felberbaum, 2015).

These systems enable the synthesis of complex proteins requiring post-translational modifications like glycosylation or proper protein folding. The insect cells provide a eukaryotic environment that closely resembles mammalian cells, resulting in higher yields of functional proteins (Gray, 2001).

Baculovirus-based expression provides tight control over gene expression by utilizing specific promoters that can be regulated at various stages of infection. Furthermore, co-infection with multiple viruses allows for the production of multi-subunit complexes and other complex protein assemblies (Sokolenko, *et al.*, 2012).

While insect cell-based expression systems may require more complex culture conditions and longer process times compared to bacteria or yeast systems, they offer a viable option for applications where correct protein folding and post-translational modifications are crucial (Korn *et al.,* 2020).

Mammalian Cell Expression Systems

Mammalian cell expression systems are highly desirable when producing therapeutic probiotics requiring specific post-translational modifications such as glycosylation patterns or disulfide bond formation to achieve optimal functionality and bioactivity (Zhu, 2012).

Chinese hamster ovary (CHO) cells are commonly employed in mammalian cell expression due to their stable growth characteristics, high productivity, and ability to perform complex post-translational modifications (Li, *et al.,* 2022).

Advancements in cell engineering and culture optimization have led to improved mammalian expression systems, allowing the production of large quantities of recombinant proteins with high purity and bioactivity. Additionally, the development of serum-free media formulations reduces the risk of contamination and simplifies downstream purification processes (Zhu, *et al.,* 2017)

Although mammalian cell expression systems may require more complex infrastructure compared to other systems due to their higher cost and lower growth rates, they remain crucial for producing therapeutic probiotics with optimal functionality and safety profiles. Furthermore, mammalian cell expression systems offer the advantage of producing glycosylated proteins with correct folding and functional activity, making them ideal for the production of biologics such as antibodies, enzymes, and vaccines (Yousefi, *et al.*, 2018). Additionally, the use of mammalian cell expression systems allows for post-translational modifications such as phosphorylation, acetylation, and glycosylation, which are crucial for the proper functioning and stability of therapeutic proteins. Furthermore, the ability of mammalian cell expression systems to accurately reproduce human-like protein modifications makes them essential in the production of biopharmaceuticals with high efficacy and minimal immunogenicity. The flexibility and scalability of mammalian cell expression systems also contribute to their suitability for large-scale production of therapeutic proteins, allowing for cost-effective and efficient manufacturing processes. Furthermore, mammalian cell expression systems have been extensively optimized and standardized, resulting in high product yields and consistent quality, which is crucial for meeting regulatory requirements and ensuring patient safety. (Khan, 2013). Additionally, mammalian cell expression systems offer post-translational modifications, such as phosphorylation and acetylation, that are necessary for the functional diversity and regulation of therapeutic proteins. These modifications contribute to the overall efficacy and specificity of the biopharmaceuticals, making mammalian cell expression systems indispensable in the development of advanced therapeutics. In conclusion, the suitability of mammalian cell expression systems for large-scale production of therapeutic proteins, along with their optimized and standardized processes, high product yields, and consistent quality, make them essential for cost-effective and efficient manufacturing processes and meeting regulatory requirements, ensuring patient safety. Additionally, the post-translational modifications facilitated by mammalian cell expression systems contribute to the overall efficacy and specificity of biopharmaceuticals, making them invaluable in the development of advanced therapeutics. Furthermore, the continuous advancements in mammalian cell expression technology are driving the development of new and improved biopharmaceuticals that can address complex diseases and provide better treatment options for patients (Zhong, *et al.*, 2023).

Expression of Recombinant Protein in Ecoli and I'ts Application

The expression of recombinant proteins in Escherichia coli, commonly known as E. coli, has revolutionized the field of biotechnology. E. coli is an ideal host organism for protein expression due to its rapid growth, well-characterized genetics, and ease of manipulation. This section will delve into the various aspects of expressing recombinant proteins in E. coli and highlight its applications in therapeutic probiotics (Hayat, *et al.,* 2018).

Expression System Design

Designing an efficient expression system is crucial for obtaining high yields of the desired recombinant protein. Elements such as choice of promoter, selection marker, fusion partners, and optimization of plasmid copy number play a pivotal role in achieving optimal expression levels. By carefully selecting these elements and optimizing their interactions, scientists can ensure robust production of the target protein (Pouresmaeil& Azizi-Dargahlou, 2023).

Protein Expression Strategies

Different strategies are employed to enhance protein yield and solubility in E. coli. These include codon optimization for improved translation efficiency, secretion systems to direct secretion into the periplasmic space or extracellular medium, and co-expression with chaperones or folding catalysts like GroEL/GroES or DsbA/DsbC enzymes (Karyolaimos& de Gier, 2021).

Purification Techniques

After successful protein expression, purification techniques are employed to isolate the recombinant protein from complex cellular components. Affinity chromatography using affinity tags such as His-Tag or GST-Tag is a popular method due to its high specificity and ease of purification. Other methods like ion-exchange chromatography and size exclusion chromatography are used for further purification steps (Kimple, *et al.,* 2013).

Application in Therapeutic Probiotics

The expression of recombinant proteins in E. coli has found significant applications in developing therapeutic probiotics. These engineered probiotics can be designed to produce beneficial proteins such as antimicrobial peptides, enzymes, or immunomodulatory factors. By utilizing E. coli as an expression host, these therapeutic probiotics can be easily optimized and scaled up for large-scale production, making them potential contenders for future medical interventions (Ohshima, et al., 2016). Diverse applications of probiotic bacteria are depicted in the Fig. 2.



Fig. 2. Application of probiotics in different sectors

Cloning, Expression, Purification and Analysis of Recombinant Microbial Enzyme

Cloning of Recombinant Microbial Enzyme

In order to express a desired microbial enzyme, it is imperative to first clone its gene into a suitable host organism, such as Escherichia coli (E. coli). This involves isolating and amplifying the target gene from its natural source through techniques like polymerase chain reaction (PCR) or restriction enzyme digestion. Subsequently, the gene is inserted into a cloning vector, which acts as a carrier to introduce the foreign DNA into the host organism (Adrio & Demain, 2014).

The choice of an appropriate cloning vector plays a crucial role in facilitating successful expression. Factors such as compatibility with the host organism, ease of manipulation, and ability to maintain stable genetic material are taken into consideration. Popular vectors include plasmids and bacteriophages, which possess desirable features like selectable markers for identifying transformed cells and promoter sequences for driving gene expression (Nora, *et al.*, 2019).

Expression of Recombinant Microbial Enzyme

Once cloned into an appropriate vector, recombinant microbial enzymes can be expressed by introducing the construct into host cells via transformation methods such as heat shock or electroporation. Following successful integration, cellular machinery recognizes and transcribes the inserted gene under appropriate conditions dictated by specific promoters within the vector (Diep, *et al.*, 2018).

To achieve high-level expression, optimizing growth conditions becomes crucial. Factors like culture medium composition, temperature, pH, and the addition of inducers or co-factors must be carefully controlled. Additionally, the choice of expression system, whether it be constitutive or inducible, further influences the level and timing of enzyme production (Jones, *et al.*, 2017).

Purification of Recombinant Microbial Enzyme

After successful expression, purification of recombinant microbial enzymes is essential to obtain a highly pure and active protein for therapeutic applications. This process involves several steps that exploit the unique characteristics of the target enzyme, such as size exclusion chromatography, ion-exchange chromatography, affinity chromatography, or a combination thereof (Wingfield, 2015).

Purification techniques meticulously separate the target enzyme from other cellular components like host proteins and nucleic acids. Multiple rounds of purification are often necessary to achieve desired levels of purity. The use of advanced technologies such as high-performance liquid chromatography (HPLC) allows for precise separation and quantification of purified enzymes (Coskun, 2016).

The successful expression and purification of recombinant microbial enzymes bring us one step closer to unlocking their vast therapeutic potential in probiotics. These biologically active molecules hold promise for a range of applications including treating gastrointestinal disorders and modulating immune responses. With continued advancements in this field, we can look forward to a future where probiotics offer personalized solutions to improve human health (Ramirez-Olea, et al., 2022).

One commonly employed method is affinity chromatography, which exploits the specific interaction between the recombinant enzyme and an immobilized ligand. The recombinant enzyme, often tagged with a polyhistidine or glutathione S-transferase (GST) tag, can be selectively bound to a resin matrix containing the corresponding affinity ligand. Through careful manipulation of buffer conditions, such as pH and ionic strength, target enzymes can be eluted with high purity and yield (Celińska, et al., 2014).

Another technique extensively used is size exclusion chromatography (SEC), also known as gel filtration chromatography. This method separates molecules based on their size differences by allowing them to pass through a porous stationary phase. Large molecules, including aggregates and contaminants, are excluded from entering the pores while smaller target enzymes can enter deeper into the matrix. Consequently, highly purified recombinant microbial enzymes can be obtained by collecting fractions containing only monomeric forms Ravindran, & Jaiswal, 2016).

In addition to these methods, ion exchange chromatography (IEC), hydrophobic interaction chromatography (HIC), and various electrophoretic techniques such as SDS-PAGE are also employed for purification purposes depending on specific requirements (Ansari, & Satar, 2012).

Analysis of Recombinant Microbial Enzyme

The analysis of recombinant microbial enzymes plays a crucial role in ensuring their quality, functionality, and efficacy for therapeutic probiotic applications. Through rigorous analytical techniques and assays, scientists can assess the expression levels, purity, stability, enzymatic activity, and structural integrity of these bioengineered entities. Such thorough analyses are imperative to validate the viability of recombinant microbial enzymes as potential therapeutic agents and instill confidence in their safe usage (Liu, et al., 2015).

One of the primary aspects of enzyme analysis involves measuring its enzymatic activity. By subjecting the recombinant microbial enzyme to specific substrate molecules under controlled conditions, scientists can assess its catalytic efficiency and kinetics. Through meticulous experimentation and advanced assays like kinetic spectrophotometry or fluorometry, they can determine key parameters such as reaction rates, Michaelis-Menten constants (KM), pH optima, temperature optima, and substrate specificity. These findings provide essential insights into the functionality and performance of the enzyme (Robinson, 2015).

In addition to enzymatic activity assays, various physicochemical characterization techniques aid in assessing the structural properties of recombinant microbial enzymes. Techniques like circular dichroism spectroscopy (CD) allow researchers to investigate their secondary structure elements such as alpha-helices and beta-sheets. Moreover, X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy enables scientists to elucidate their three-dimensional structures with high precision. Such detailed analysis not only confirms correct folding but also helps identify potential areas for improvements or modifications (Mohamad, 2015).

To ensure product quality and safety for therapeutic use in humans or animals, comprehensive purity assessments are performed on recombinant microbial enzymes. Techniques such as SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis), HPLC (High-Performance Liquid Chromatography), or mass spectrometry aid in determining the presence of impurities, such as host cell proteins, nucleic acids, or other contaminants. These analyses ensure that the final enzyme product meets stringent regulatory standards and is free from potential allergenic or toxic components (Alhazmi, &Albratty, 2023).

Achievement of High-Level Expression of Microbial Enzyme

Expressing recombinant microbial enzymes at high levels is a key milestone in the field of therapeutic probiotics. The ability to produce substantial amounts of these enzymes not only ensures their availability for various applications but also enhances their effectiveness. Achieving high-level expression demands meticulous optimization of several factors, including host selection, promoter strength, codon usage, and fermentation conditions (Nigam, 2013).

One crucial aspect in achieving high-level expression is the choice of an appropriate microbial host. Escherichia coli (E. coli) emerges as a popular choice due to its well-established genetics, ease of genetic manipulation, rapid growth rate, and cost-effective production. By selecting a well-characterized E. coli strain, researchers can leverage existing knowledge to tune the expression system effectively (Chen, *et al.,* 2020).

Promoter strength plays a vital role in driving gene expression levels. Employing strong promoters such as T7 or lac can significantly enhance the production of recombinant microbial enzymes. Furthermore, optimizing codon usage to match that of the chosen host organism can further boost protein synthesis efficiency by overcoming potential mRNA instability or translational barriers (Bienick, *et al., 2*014).

Fermentation conditions are another critical factor influencing enzyme expression levels. Parameters such as temperature, pH, dissolved oxygen levels, and inducer concentration must be carefully optimized to ensure favorable growth conditions and maximize enzyme production rates. Additionally, continuous monitoring and control strategies can be implemented to optimize nutrient supply and maintain metabolic activity throughout the fermentation process (Steffen, *et al.*, 2017).

Applications of Recombinant Microbial Enzyme

The field of recombinant microbial enzymes holds immense promise in various industries and fields, showcasing a wide array of potential applications. Through the advancements in biotechnology, these modified enzymes exhibit enhanced catalytic properties and specificity, making them invaluable tools for numerous purposes. Let us delve into some of the exciting areas where the application of recombinant microbial enzymes is revolutionizing the world (Borrelli, & Trono, 2015).

Industrial Applications

In industrial settings, recombinant microbial enzymes find extensive utility due to their exceptional efficiency and versatility. These enzymes are employed in diverse sectors such as food processing, detergent formulation, biofuel production, and textile manufacturing. The introduction of recombinant strains allows for cost-effective production on a large scale while reducing environmental impact. Moreover, their improved stability and compatibility with various substrates provide industries with sustainable solutions that enhance productivity without compromising quality (Schillberg, & Finnern, (2021).

Biopharmaceuticals Production

The use of recombinant microbial enzymes plays a crucial role in the production of biopharmaceuticals – complex therapeutic molecules that are synthesized by living organisms such as bacteria or yeast. These enzymes aid in genetically engineering host cells to produce high-value therapeutic proteins like insulin, growth hormones, antibodies, and vaccines. By utilizing recombinant techniques, we can achieve higher expression levels and ensure accurate protein folding for enhanced efficacy and safety in medical treatments (Rosales, *et al.,* 2016).

Environmental Remediation

Recombinant microbial enzymes have emerged as powerful tools for combating environmental pollutants by facilitating bioremediation processes. Certain microorganisms possess natural capabilities to degrade harmful compounds; however, their efficiency can be further enhanced through genetic modifications using recombinant technology. This approach enables the development of robust enzyme systems capable of breaking down contaminants such as pesticides, petroleum hydrocarbons, and heavy metals. Harnessing the potential of recombinant enzymes in environmental remediation offers a sustainable and eco-friendly solution to protect our ecosystems (Bala, *et al.*, 2022).

Therapeutic Probiotics

A particularly exciting area of application for recombinant microbial enzymes lies in the production of therapeutic probiotics. These genetically engineered probiotics are designed to deliver specific therapeutic benefits by expressing recombinant enzymes within the human body. By targeting various conditions such as lactose intolerance, inflammatory bowel diseases, and immune system modulation, these probiotics hold great potential for improving overall health and well-being. The precise control over enzyme expression allows for tailored treatments with minimal side effects, offering new avenues for personalized medicine (Barra, *et al.,* 2020).

In conclusion, the potential applications of recombinant microbial enzymes are vast and promising across multiple industries and fields. From industrial processes to healthcare advancements and environmental sustainability, these modified enzymes are transforming various areas of human endeavor. Through ongoing research and innovation in biotechnology, we can continue to unlock the immense potential of recombinant microbial enzymes – paving the way towards a brighter future where science empowers us to solve complex challenges in a sustainable and efficient manner (Davoodvandi, *et al.*, 2021).

Clinical Applications of Recombinant Probiotics

Recombinant probiotics have emerged as a promising tool in the field of clinical applications, offering a wide range of therapeutic benefits. These genetically engineered microorganisms exhibit enhanced capabilities to deliver targeted treatments and alleviate various health conditions. From gastrointestinal disorders to immune system modulation, recombinant probiotics are paving the way for innovative approaches to patient care (Mugwanda, *et al.,* 2023).

Gastrointestinal Disorders

In the realm of gastrointestinal disorders, recombinant probiotics have shown tremendous potential in providing relief and improving overall digestive health. Through genetic modification, these probiotics can produce specific enzymes or molecules that aid in the breakdown of complex carbohydrates, proteins, and fats. This enhances nutrient absorption and reduces symptoms related to conditions such as lactose intolerance, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD) (Kitazawa, *et al.,* 2015).

Orating specific genes encoding therapeutic enzymes into probiotic strains, it becomes conceivable to treat a wide range of health conditions at their root cause. Imagine a future where individuals with lactose intolerance can consume aMoreover, recombinant probiotics can be engineered to deliver therapeutic compounds directly to affected areas of the gastrointestinal tract. For instance, they can produce antimicrobial peptides that combat harmful bacteria or release anti-inflammatory agents that address gut inflammation. This targeted approach holds great promise for personalized medicine in treating conditions like Clostridium difficile infection, ulcerative colitis, and Crohn's disease (Oak, & Jha, 2019).

Immune System Modulation

The immune-enhancing properties of recombinant probiotics have sparked considerable interest in their potential for modulating immune responses. By expressing specific immunomodulatory molecules or antigens derived from pathogens, these modified probiotic strains can stimulate or suppress immune cells' activity (Mazziotta, *et al.,* 2023).

This technology opens doors for innovative strategies in treating autoimmune diseases like multiple sclerosis or rheumatoid arthritis by suppressing aberrant immune responses. Furthermore, recombinant probiotics hold promise for developing novel vaccines against infectious diseases by delivering antigenic proteins directly to the gut-associated lymphoid tissues, which are crucial for immune response activation (Yeşilyurt, *et al.,* 2021)

Metabolic Disorders

Recombinant probiotics also offer exciting possibilities for addressing metabolic disorders such as obesity and diabetes. Through genetic engineering, these microbial agents can produce or enhance the production of bioactive compounds that regulate metabolic pathways (Cerdó, *et al.,* 2019).

For instance, recombinant probiotics can be engineered to secrete important enzymes involved in lipid metabolism, promoting fat breakdown and reducing adiposity. They can also produce peptides that enhance insulin sensitivity or regulate appetite, aiding in weight management and blood sugar control. With obesity and diabetes becoming increasingly prevalent worldwide, recombinant probiotics hold immense potential as a natural and targeted approach to combating these conditions (Megur, et al., 2022).

In conclusion, the clinical applications of recombinant probiotics are vast and hold great promise for revolutionizing healthcare. From gastrointestinal disorders to immune system modulation and metabolic disorders, these genetically modified microorganisms offer tailored solutions to complex health challenges. As research continues to advance in this field, we can anticipate further breakthroughs that will improve patient outcomes and contribute to a brighter future in personalized medicine (Sleator, 2015).

Future Scope Of Recombinant Probiotics

The field of recombinant probiotics holds immense promise for the future, with numerous exciting avenues of exploration and application on the horizon. As our understanding of the human microbiome deepens, so does our awareness of the potential therapeutic benefits that can be harnessed through the use of recombinant microbial enzymes in probiotics (Cunningham, *et al.,* 2021)

One captivating aspect lies in the possibility of developing personalized probiotics tailored to individual needs. By incorp personalized probiotic that produces lactase, allowing them to enjoy dairy products without discomfort (Porzi, *et al.,* 2021)

Another fascinating direction for future research involves engineering recombinant probiotics to target and neutralize pathogens in the gut. By introducing genes encoding antimicrobial peptides or enzymes with potent antibacterial properties, these genetically modified organisms could act as living antibiotics within the body. Such an approach could potentially revolutionize how we combat antibiotic-resistant bacteria and reduce reliance on traditional antibiotic treatments (Lynch, et al., 2022).

The integration of recombinant microbial enzymes into food production processes represents yet another promising avenue for the future. By modifying food-grade microorganisms to express enzymes that enhance digestion or improve nutrient absorption, it is possible to develop functional foods with enhanced health benefits. These foods could play a pivotal role in addressing nutritional deficiencies and promoting overall well-being (Raveendran, *et al.*, 2018).

4. Conclusion

In conclusion, the expression, purification, and analysis of recombinant microbial enzymes for the application of therapeutic probiotics hold immense promise and potential in the field of biotechnology. The successful cloning and expression of these enzymes in E. coli opens up avenues for further research and development, with the ultimate goal of harnessing their therapeutic benefits. The purification process ensures the isolation of highly active and pure enzymes, paving the way for their safe and effective utilization. Through rigorous analysis, we gain valuable insights into the molecular properties and mechanisms underlying these enzymes, enabling us to optimize their performance for various applications. With ongoing advancements in recombinant technology, we stand on the cusp of a new era where probiotics armed with these microbial enzymes can revolutionize healthcare by delivering targeted therapies while promoting overall well-being. This exciting field offers a glimpse into a future where precision medicine meets natural symbiosis – a vision that leaves us hopeful about the endless possibilities that lie ahead.

In conclusion, it is evident that our pursuit of purifying and optimizing microbial enzymes holds immense potential for revolutionizing healthcare through targeted therapies and overall well-being promotion. The ongoing advancements in recombinant technology offer a glimpse into a future where precision medicine and natural symbiosis converge, opening up endless possibilities. In conclusion, it is evident that our pursuit of purifying and studying enzymes holds great promise for advancing healthcare through targeted therapies and overall well-being, ushering in a future where precision medicine and natural symbiosis intersect to offer endless possibilities. In conclusion, it is evident that our pursuit of highly active and pure enzymes through purification processes, combined with advances in recombinant technology, holds immense potential for revolutionizing healthcare through targeted therapies and promoting overall well-being. This exciting field offers a promising future where precision medicine and natural symbiosis merge, bringing endless possibilities. In conclusion, it is evident that our pursuit of purifying and optimizing microbial enzymes holds tremendous potential for transforming healthcare through targeted therapies and overall well-being, heralding a future where precision medicine and natural symbiosis merge to unlock limitless possibilities. of understanding and harnessing the power of microbial enzymes holds great promise for improving healthcare and wellness through targeted therapies and precision medicine. The potential for probiotics armed with these enzymes to revolutionize the field gives hope for an exciting future of natural symbiosis and endless possibilities. In conclusion, it is evident that our pursuit of purifying and optimizing microbial enzymes holds immense potential for transforming healthcare through targeted therapies and promoting verall well-being. The ongoing advancements in recombinant technology offer a promising future where precision medicine and natural symbiosis intersect, opening doors to countless possibilities.

References:

Adrio, J. L., & A. L .Demain, 2014. Microbial enzymes: tools for biotechnological processes. Biomolecules., *4*(1):117–139. https://doi.org/10.3390/biom4010117

Alhazmi, H. A., & M. Albratty, 2023. Analytical Techniques for the Characterization and Quantification of Monoclonal Antibodies. Pharmaceuticals (Basel, Switzerland*).*, *16*(2), 291. https://doi.org/10.3390/ph16020291

Andreasen, A. S., N. Larsen., T. Pedersen-Skovsgaard., R.M. Berg., K. Møller., K.D. Svendsen., M. Jakobsen & B.K. Pedersen. 2010. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. British journal of nutrition., 104: 1831-1838.

Ansari, S. A., & R.Satar, 2012. Recombinant β-galactosidases – Past, present and future: A mini review. Journal of Molecular Catalysis B-enzymatic., 81: 1–6. https://doi.org/10.1016/j.molcatb.2012.04.012

Ayyash, M., A.Abushelaibi., S.Al-mahadin.,M.Enan., K.El-tarabily & N. Shah. 2018. In-vitro investigation into probiotic characterisation of Streptococcus and Enterococcus isolated from camel milk. LWT., 87:478-487.

Baghban, R., S.Farajnia, M. Rajabibazl., Y.Ghasemi., A. Mafi., R.Hoseinpoor., L.Rahbarnia & M.Aria. 2019. Yeast Expression Systems: Overview and Recent Advances. Molecular biotechnology., 61(5):365–384. https://doi.org/10.1007/s12033-019-00164-8
Bala, S., D.Garg., B.V.Thirumalesh, M.Sharma., K. Sridhar., B.S.Inbaraj, & M.Tripathi. 2022. Recent Strategies for Bioremediation of Emerging Pollutants: A Review for a Green and Sustainable Environment. Toxics., 10(8): 484. https://doi.org/10.3390/toxics10080484
Baral, K. C., R.Bajracharya., S.H.Lee., & H.K.Han. 2021. Advancements in the Pharmaceutical Applications of Probiotics: Dosage Forms and Formulation Technology. International journal of nanomedicine., 16:7535–7556. https://doi.org/10.2147/IJN.S337427
Barra, M., T.Danino. & D.Garrido. 2020. Engineered Probiotics for Detection and Treatment of Inflammatory Intestinal Diseases. Frontiers in bioengineering and biotechnology., 8: 265. https://doi.org/10.3389/fbioe.2020.00265
Basturk, A., R. Artan & A. Yilmaz. 2016. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol., 27: 439-443.
Behnsen, J., E.Deriu., M.Sassone-Corsi., & M.Raffatellu. 2013. Probiotics: properties, examples, and specific applications. Cold Spring Harbor perspectives in medicine., 3(3), a010074. https://doi.org/10.1101/cshperspect.a010074
Bienick, M. S., K.W.Young., J.R.Klesmith., E.E.Detwiler., K.J.Tomek., & T.A. Whitehead. 2014. The interrelationship between promoter strength, gene expression, and growth rate. PloS one., 9(10), e109105. https://doi.org/10.1371/journal.pone.0109105
Borrelli, G. M., & D.Trono. 2015. Recombinant lipases and phospholipases and their use as biocatalysts for industrial applications. International Journal of Molecular Sciences., 16(9):20774–20840. https://doi.org/10.3390/ijms160920774
Briand, L., G.Marcion, A.Kriznik, J.M. Heydel, Y.Artur., C.Garrido., R.Seigneuric., & F. Neiers. 2016. A self-inducible heterologous protein expression system in Escherichia coli. Scientific reports., 6: 33037. https://doi.org/10.1038/srep33037
Cayzeele-Decherf, A., F. Pélerin., S.Leuillet., B.Douillard., B. Housez., M.Cazaubiel., G.Jacobson., P.Jüsten & P. Desreumaux. 2017. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis. World journal of gastroenterology., 23, 336.
Celińska, E., W.Bialas., M.Borkowska., & W.Grajek. 2014. Cloning, expression, and purification of insect (Sitophilus oryzae) alpha-amylase, able to digest granular starch, in Yarrowialipolytica host. Applied Microbiology and Biotechnology., 99(6):2727–2739. https://doi.org/10.1007/s00253-014-6314-2
Cerdó, T., J.A.García-Santos., M.García-Bermúdez., & C.Campoy. 2019. The role of probiotics and prebiotics in the prevention and treatment of obesity. Nutrients., 11(3):635. https://doi.org/10.3390/nu11030635
Chen, R., S.Yang., L.Zhang., & Y.J.Zhou., 2020. Advanced strategies for production of natural products in Yeast. Science., 23(3): 100879. https://doi.org/10.1016/j.isci.2020.100879
Clapp, M., N.Aurora., L.Herrera., M.Bhatia., E.Wilen., & S.Wakefield. 2017. Gut microbiota's effect on mental health: The gut-brain axis. Clinics and practice., 7(4): 987. https://doi.org/10.4081/cp.2017.987
Coskun O. 2016. Separation techniques: Chromatography. Northern clinics of Istanbul., 3(2), 156–160. https://doi.org/10.14744/nci.2016.32757
Cunningham, M., M.A.Azcarate-Peril., A.Barnard., V.Benoit., R.Grimaldi., D.Guyonnet, H.D.Holscher., K.Hunter., S.Manurung., D.Obis., M.I.Petrova., R.E.Steinert., K.Swanson., D.van Sinderen., J.Vulevic,., & G.R.Gibson. 2021. Shaping the Future of Probiotics and Prebiotics. Trends in microbiology., 29(8):667–685. https://doi.org/10.1016/j.tim.2021.01.003
Davoodvandi, A., H.Marzban., P.Goleij., A.Sahebkar., K.Morshedi., S.Rezaei., M.Mahjoubin-Tehran., H.Tarrahimofrad., M.R.Hamblin., & H.Mirzaei. 2021. Effects of therapeutic probiotics on modulation of microRNAs. Cell Communication and Signaling., 19(1). https://doi.org/10.1186/s12964-020-00668-w
Dermyshi, E., Y.Wang., C.Yan., W.Hong., G.Qiu., X.Gong., & T.Zhang. 2017. The "Golden Age" of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants. Neonatology., 112(1): 9–23. https://doi.org/10.1159/000454668
Diep, P., R.Mahadevan., & A.F.Yakunin.2018. Heavy metal removal by bioaccumulation using genetically engineered microorganisms. Frontiers in Bioengineering and Biotechnology., *6*. https://doi.org/10.3389/fbioe.2018.00157
Ezzamouri, B., S.Shoaie., & R. Ledesma-Amaro.2021. Synergies of Systems Biology and Synthetic Biology in Human Microbiome Studies. Frontiers in microbiology., 12: 681982. https://doi.org/10.3389/fmicb.2021.681982
Fakruddin, M., R.Mohammad Mazumdar., K.S.Bin Mannan.,A.Chowdhury., & M.N.Hossain. 2012. Critical Factors Affecting the Success of Cloning, Expression, and Mass Production of Enzymes by Recombinant E. coli. ISRN biotechnology., *2013*, 590587. https://doi.org/10.5402/2013/590587

Fan, Q., P.Neubauer., & M.Gimpel. 2021. Production of soluble regulatory hydrogenase from Ralstoniaeutropha in Escherichia coli using a fed-batch-based autoinduction system. Microbial cell factories., *20*(1): 201. https://doi.org/10.1186/s12934-021-01690-4

Felberbaum R. S. 2015. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnology journal., 10(5):702–714. https://doi.org/10.1002/biot.201400438

Fenster, K., B.Freeburg., C.Hollard., C.Wong., R.Rønhave Laursen., & A.C.Ouwehand. 2019. The Production and Delivery of Probiotics: A Review of a Practical Approach. Microorganisms., 7(3), 83. https://doi.org/10.3390/microorganisms7030083

Ferraro, G., N.Demitri., L.Vitale., G.Sciortino., D.Sanna., V.Ugone., E.Garribba., & A.Merlino. 2021. Spectroscopic/Computational Characterization and the X-ray Structure of the Adduct of the $V^{IV}O$-Picolinato Complex with RNase A. Inorganic chemistry., 60(24): 19098–19109. https://doi.org/10.1021/acs.inorgchem.1c02912

Gagliardi, A., V.Totino., F.Cacciotti., V.Iebba., B.Neroni., G.Bonfiglio., M.Trancassini., C.Passariello., F.Pantanella., & S.Schippa. 2018. Rebuilding the Gut Microbiota Ecosystem. International journal of environmental research and public health., 15(8): 1679. https://doi.org/10.3390/ijerph15081679

Górska, A., D.Przystupski, M.J.Niemczura., & J.Kulbacka. 2019. Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy. Current microbiology., 76(8): 939–949. https://doi.org/10.1007/s00284-019-01679-8

Goyal, M., M. Bansal., S. Yadav & K. Malhotra. 2012. Probiotics: The friendly microbes. Indian Journal of Clinical Practice., 23: 126-130

Gray D. 2001. Overview of protein expression by mammalian cells. Current protocols in protein science, Chapter 5(1): Unit5.9. https://doi.org/10.1002/0471140864.ps0509s10

Hayat, S. M. G., N.Farahan.i, B.Golichenari., & A.Sahebkar. 2018. Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to Know. Current pharmaceutical design., 24(6),:718–725. https://doi.org/10.2174/1381612824666180131121940

Hemarajata, P., & J.Versalovic. 2013. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therapeutic advances in gastroenterology., 6(1):39–51. https://doi.org/10.1177/1756283X12459294

Hlivak, P., J. Odraska., M.Ferencik., L.Ebringer., E.Jahnova & Z.Mikes. 2005. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl Lek Listy., 106: 67-72.

Horwitz, A. A., J.M. Walter., M.G.Schubert., S.H.Kung., K. Hawkins., D.Platt., A.D.Hernday., T.Mahatdejkul-Meadows., W.Szeto., S.S. Chandran., & J.D.Newman. 2015. Efficient multiplexed integration of synergistic alleles and metabolic pathways in yeasts via CRISPR-CAS. Cell Systems., 1(1): 88–96. https://doi.org/10.1016/j.cels.2015.02.001

Jones, J. A., V.R. Vernacchio., S.M. Collins., A.N. Shirke., Y. Xiu, J.A.Englaender., B.F.Cress., C.C. McCutcheon., R.J. Linhardt., R.A.Gross., & M.A.G. Koffas. 2017. Complete Biosynthesis of Anthocyanins Using *E. coli* Polycultures. MBio., 8(3). https://doi.org/10.1128/mbio.00621-17

Jonkers, D., & R.Stockbrügger. 2003. Probiotics and inflammatory bowel disease. Journal of the Royal Society of Medicine., 96(4): 167–171.

Kadooka, Y., M. Sato., K. Imaizumi., A. Ogawa., K. Ikuyama., Y. Akai., M. Okano., M. Kagoshima. & T. Tsuchida. 2010. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. European journal of clinical nutrition., 64, 636.

Kago, G., C.L. Turnbough., & S.M. Payne. 2023. (p)ppGpp is required for Virulence of Shigella flexneri. *bioRxiv (Cold Spring Harbor Laboratory)*. https://doi.org/10.1101/2023.08.24.554660

Kahouli, I., C. Tomaro-Duchesneau & S. Prakash. 2013. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol., 62:1107-23.

Kali A. 2015. Human Microbiome Engineering: The Future and Beyond. Journal of clinical and diagnostic research JCDR., 9(9): DE01–DE4. https://doi.org/10.7860/JCDR/2015/14946.6570

Karyolaimos, A., & J.W. de Gier. 2021. Strategies to Enhance Periplasmic Recombinant Protein Production Yields in Escherichia coli. Frontiers in bioengineering and biotechnology., 9, 797334. https://doi.org/10.3389/fbioe.2021.797334

Khan K. H. 2013. Gene expression in Mammalian cells and its applications. Advanced pharmaceutical bulletin., 3(2):257–263. https://doi.org/10.5681/apb.2013.042

Kimple, M. E., A.L. Brill., & R.L.Pasker. 2013. Overview of affinity tags for protein purification. Current protocols in protein science., 73: 9.9.1–9.9.23. https://doi.org/10.1002/0471140864.ps0909s73

Kitazawa, H., S. Alvarez., A.Suvorov., V.G.Mel'nikov., J.Villena., & B.Sánchez. 2015. Recent advances and future perspective in microbiota and probiotics. BioMed Research International., 1–2. https://doi.org/10.1155/2015/275631

Korn, J., D.Schäckermann., T.Kirmann., F.Bertoglio,, S.Steinke., J.Heisig., M.Ruschig., G. Rojas., N.Langreder., E.V. Wenzel., K.D. Roth., M.Becker., D. Meier., J.Van Den Heuvel., Hust., S.Dübel., & M.Schubert. 2020. Baculovirus-free insect cell expression system for high yield antibody and antigen production. Scientific Reports., 10(1). https://doi.org/10.1038/s41598-020-78425-9
Kumar, A., J.Pramanik., N.Goyal, D.Chauhan., B.S. Sivamaruthi., B.G.Prajapati., & C. Chaiyasut. 2023. Gut Microbiota in Anxiety and Depression: Unveiling the Relationships and Management Options. Pharmaceuticals (Basel, Switzerland)., 16(4): 565. https://doi.org/10.3390/ph16040565
Li, Z. M., Z.L.Fan., X.Y. Wang., & T.Y. Wang. 2022. Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells. Frontiers in bioengineering and biotechnology., 10: 880155. https://doi.org/10.3389/fbioe.2022.880155
Licciardi, P. V., I.H. Ismail., A. Balloch., M.Mui., E.Hoe., K.Lamb & M.L.Tang. 2013. Maternal supplementation with lgg reduces vaccine-specific immune responses in infants at high-risk of developing allergic disease. Front Immunol., 4, 381.
Lin, Y., Y. Feng., L.Zheng., M. Zhao., & M. Huang. 2023. Improved protein production in yeast using cell engineering with genes related to a key factor in the unfolded protein response. Metabolic engineering., 77: 152–161. https://doi.org/10.1016/j.ymben.2023.04.004
Liu, F., X. Wu., L.Li., Z.Liu., & Z.Wang. 2013. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein expression and purification., 90(2):104–116. https://doi.org/10.1016/j.pep.2013.05.009
Liu, J. R., B.Yu., F.Liu., K.J.Cheng., & X.Zhao. 2005. Expression of rumen microbial fibrolytic enzyme genes in probiotic *Lactobacillus reuteri*. Applied and environmental microbiology., 71(11):6769–6775. https://doi.org/10.1128/AEM.71.11.6769-6775.2005
Liu, L., H. Yang., H.D.Shin., R.R.Chen., J.Li., G.Du., & J.Chen. 2013. How to achieve high-level expression of microbial enzymes: strategies and perspectives. Bioengineered., 4(4): 212–223. https://doi.org/10.4161/bioe.24761
Lynch, J. P., L.Goers., & C.F.Lesser. 2022. Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics. Trends in pharmacological sciences., 43(9):772–786. https://doi.org/10.1016/j.tips.2022.02.002
Mahmood, T., & P.C. Yang. 2012. Western blot: technique, theory, and trouble shooting. North American journal of medical sciences., 4(9): 429–434. https://doi.org/10.4103/1947-2714.100998
Mazziotta, C., M. Tognon., F.Martini., E. Torreggiani., & J.C. Rotondo. 2023. Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health. Cells, 12(1), 184. https://doi.org/10.3390/cells12010184
Megur, A., E.B. Dalir.i, D. Baltriukienė., & A. Burokas. 2022. Prebiotics as a Tool for the Prevention and Treatment of Obesity and Diabetes: Classification and Ability to Modulate the Gut Microbiota. International journal of molecular sciences., 23(11): 6097. https://doi.org/10.3390/ijms23116097
Mohamad, N. R., N.H. Marzuki., N.A. Buang., F.Huyop., & R.A. Wahab. 2015. An overview of technologies for immobilization of enzymes and surface analysis techniques for immobilized enzymes. Biotechnology, biotechnological equipment., 29(2): 205–220. https://doi.org/10.1080/13102818.2015.1008192
Mugwanda, K., S. Hamese., W.F. Van Zyl., E. Prinsloo., M.Du Plessis., L.M.T. Dicks., & D.B. Thimiri Govinda Raj. 2023. Recent advances in genetic tools for engineering probiotic lactic acid bacteria. Bioscience reports., 43(1), BSR20211299. https://doi.org/10.1042/BSR20211299
Niazi Amraii, H., H. Abtahi., P. Jafari., H.R. Mohajerani., M.R. Fakhroleslam., & N. Akbari, 2014. In Vitro Study of Potentially Probiotic lactic Acid Bacteria Strains Isolated From Traditional Dairy Products. Jundishapur journal of microbiology, 7(6), e10168. https://doi.org/10.5812/jjm.10168
Nigam P. S. 2013. Microbial enzymes with special characteristics for biotechnological applications. Biomolecules., 3(3): 597–611. https://doi.org/10.3390/biom3030597
Nora, L. C., C.A. Westmann., L. Martins-Santana., L.F. Alves., L.M.O. Monteiro., M.E. Guazzaroni., & R. Silva-Rocha. 2019. The art of vector engineering: towards the construction of next-generation genetic tools. Microbial biotechnology., 12(1): 125–147. https://doi.org/10.1111/1751-7915.13318
Nouemssi, S. B., M. Ghribi., R. Beauchemin., F.Meddeb-Mouelhi., H.Germain., & I. Desgagné-Penix. 2020. Rapid and Efficient Colony-PCR for High Throughput Screening of Genetically Transformed Chlamydomonas reinhardtii. Life (Basel, Switzerland), 10(9), 186. https://doi.org/10.3390/life10090186
Oak, S. J., & R. Jha. 2019. The effects of probiotics in lactose intolerance: A systematic review. Critical reviews in food science and nutrition, 59(11): 1675–1683. https://doi.org/10.1080/10408398.2018.1425977
Ohshima, T., Y. Kojima., C.J. Seneviratne., & N.Maeda., 2016. Therapeutic application of synbiotics, a fusion of probiotics and prebiotics, and biogenics as a new concept for oral candida infections: a mini review. Frontiers in Microbiology., 7. https://doi.org/10.3389/fmicb.2016.00010

Parapouli, M., A. Vasileiadis., A.S.Afendra., & E. Hatziloukas. 2020. Saccharomyces cerevisiae and its industrial applications. AIMS microbiology., 6(1): 1–31. https://doi.org/10.3934/microbiol.2020001
Pina, A. S., C.R. Lowe., & A.C. Roque. 2014. Challenges and opportunities in the purification of recombinant tagged proteins. Biotechnology advances., 32(2): 366–381. https://doi.org/10.1016/j.biotechadv.2013.12.001
Plaza-Diaz, J., F.J. Ruiz-Ojeda., M. Gil-Campos., & A. Gil. 2019. Mechanisms of Action of Probiotics. Advances in nutrition (Bethesda, Md.), 10(suppl_1), S49–S66. https://doi.org/10.1093/advances/nmy063
Porzi, M., K.J. Burton-Pimentel., B.Walther., & G. Vergères. 2021. Development of Personalized Nutrition: Applications in Lactose Intolerance Diagnosis and Management. Nutrients., 13(5): 1503. https://doi.org/10.3390/nu13051503
Pouresmaeil, M., & S. Azizi-Dargahlou. 2023. Factors involved in heterologous expression of proteins in E. coli host. Archives of microbiology., 205(5): 212. https://doi.org/10.1007/s00203-023-03541-9
Quigley E. M. 2013. Gut bacteria in health and disease. Gastroenterology & hepatology., 9(9): 560–569.
Ramirez-Olea, H., B.Reyes-Ballesteros., & R.A. Chavez-Santoscoy. 2022. Potential application of the probiotic Bacillus licheniformis as an adjuvant in the treatment of diseases in humans and animals: A systematic review. Frontiers in microbiology., 13: 993451. https://doi.org/10.3389/fmicb.2022.993451
Raveendran, S., B. Parameswaran., S.B. Ummalyma., A. Abraham., A.K. Mathew., A. Madhavan, S. Rebello., & A. Pandey. 2018. Applications of Microbial Enzymes in Food Industry. Food technology and biotechnology., 56(1): 16–30. https://doi.org/10.17113/ftb.56.01.18.5491
Ravindran, R., & A.K. Jaiswal. 2016. Microbial enzyme production using lignocellulosic food industry wastes as feedstock: A review. Bioengineering., 3(4): 30. https://doi.org/10.3390/bioengineering3040030
Robinson P. K. 2015. Enzymes: principles and biotechnological applications. Essays in biochemistry., 59: 1–41. https://doi.org/10.1042/bse0590001
Romero-Luna, H. E., A. Hernández-Mendoza., A.F.González-Córdova., & A. Peredo-Lovillo. 2021. Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review. Food chemistry., X, 13, 100196. https://doi.org/10.1016/j.fochx.2021.100196
Rosales-Mendoza, S., C. Angulo., & B.Meza. 2016. Food-Grade organisms as vaccine biofactories and oral delivery vehicles. Trends in Biotechnology., 34(2): 124–136. https://doi.org/10.1016/j.tibtech.2015.11.007
Rosano, G. L., & E.A. Ceccarelli. 2014. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in microbiology., 5, 172. https://doi.org/10.3389/fmicb.2014.00172
Rowland, I., G. Gibson., A. Heinken., K.Scott., J.Swann., I.Thiele., & K.Tuohy. 2018. Gut microbiota functions: metabolism of nutrients and other food components. European journal of nutrition, 57(1), 1–24. https://doi.org/10.1007/s00394-017-1445-8
Satish Kumar, L., L.S. Pugalenthi., M. Ahmad., S. Reddy., Z. Barkhane., & J. Elmadi. 2022. Probiotics in Irritable Bowel Syndrome: A Review of Their Therapeutic Role. Cureus., 14(4): 24240. https://doi.org/10.7759/cureus.24240
Schillberg, S., & R. Finnern. 2021. Plant molecular farming for the production of valuable proteins – Critical evaluation of achievements and future challenges. Journal of Plant Physiology., 258–259, 153359. https://doi.org/10.1016/j.jplph.2020.153359
Shintani, M., Z.K. Sanchez., & K. Kimbara. 2015. Genomics of microbial plasmids: classification and identification based on replication and transfer systems and host taxonomy. Frontiers in microbiology., 6, 242. https://doi.org/10.3389/fmicb.2015.00242
Singh, R. P., A. Shadan., & Y. Ma. 2022. Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic Abnormality. Probiotics and antimicrobial proteins., 14(6): 1184–1210. https://doi.org/10.1007/s12602-022-09992-8
Singh, V., S. Haque., R.Niwas., A. Srivastava., M. Pasupuleti., & C.K. Tripathi. 2017. Strategies for Fermentation Medium Optimization: An In-Depth Review. Frontiers in microbiology., 7, 2087. https://doi.org/10.3389/fmicb.2016.02087
Sirajuddin, S. A., & S. Sundram. 2020. Evaluation of two transformation protocols and screening of positive plasmid introduction into Bacillus cereus EB2, a gram-positive bacterium using qualitative analyses. Brazilian journal of microbiology., [publication of the Brazilian Society for Microbiology], 51(3): 919–929. https://doi.org/10.1007/s42770-020-00241-0
Sleator R. D. 2015. Designer probiotics: Development and applications in gastrointestinal health. World journal of gastrointestinal pathophysiology., 6(3): 73–78. https://doi.org/10.4291/wjgp.v6.i3.73
Soemarie, Y. B., T. Milanda., & M. Barliana. 2021. Fermented Foods as Probiotics: A Review. Journal of advanced pharmaceutical technology & research, 12(4), 335–339. https://doi.org/10.4103/japtr.japtr_116_21
Sokolenko, S., S. George., A. Wagner., A.Tuladhar., J.M. Andrich., & M.G. Aucoin. 2012. Co-expression vs. co-infection using Baculovirus expression vectors in insect cell culture: Benefits and

drawbacks. Biotechnology advances, 30(3): 766–781. https://doi.org/10.1016/j.biotechadv.2012.01.009
Solanki, P., C. Putatunda., A. Kumar., R. Bhatia., & A. Walia. 2021. Microbial proteases: ubiquitous enzymes with innumerable uses. 3 Biotech., 11(10): 428. https://doi.org/10.1007/s13205-021-02928-z
Steffen, W., F.C. Ko., J.Patel., V.Lyamichev., T.Albert., J.Benz., M. Rudolph., F.Bergmann., T.Streidl, P.Kratzsch., M.Boenitz-Dulat., T. Oelschlaegel., & M. Schraeml. 2017. Discovery of a microbial transglutaminase enabling highly site-specific labeling of proteins. Journal of Biological Chemistry., 292(38): 15622–15635. https://doi.org/10.1074/jbc.m117.797811
Tegegne, B. A., & B. Kebede. 2022. Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature. Heliyon., 8(6), e09725. https://doi.org/10.1016/j.heliyon.2022.e09725
Thursby, E., & N. Juge. 2017. Introduction to the human gut microbiota. The Biochemical journal., 474(11): 1823–1836. https://doi.org/10.1042/BCJ20160510
Uccello, M., G. Malaguarnera., F. Basile., V.Dagata., M.Malaguarnera., G.Bertino., M.Vacante., F.Drago & A. Biondi. 2012. Potential role of probiotics on colorectal cancer prevention. BMC Surg, 12 Suppl 1, S35.
Vieira Gomes, A. M., T. Souza Carmo., L.Silva Carvalho., F.Mendonça Bahia., & N.S. Parachin. 2018. Comparison of Yeasts as Hosts for Recombinant Protein Production. Microorganisms., 6(2): 38. https://doi.org/10.3390/microorganisms6020038
Wang, X., P.Zhang., & X. Zhang. 2021. Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity. Molecules (Basel, Switzerland), 26(19), 6076. https://doi.org/10.3390/molecules26196076
Wingfield P. T. 2015. Overview of the purification of recombinant proteins. Current protocols in protein science., 80: 6.1.1–6.1.35. https://doi.org/10.1002/0471140864.ps0601s80
Yeşilyurt, N., B. Yılmaz., D.Ağagündüz., & R. Capasso. 2021. Involvement of probiotics and postbiotics in the immune system modulation. Biologics., 1(2): 89–110. https://doi.org/10.3390/biologics1020006
Yousefi, B., M. Eslami., A. Ghasemian., P.Kokhaei., A.S. Farrokhi., & N.Darabi. 2018. Probiotics importance and their immunomodulatory properties. Journal of Cellular Physiology., 234(6): 8008–8018. https://doi.org/10.1002/jcp.27559
Zhong, Q., X. Xiao., Y. Qiu., Z. Xu., C. Chen., B.Chong., X. Zhao., S. Hai., S. Li, Z. An., & L. Dai. 2023. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications., MedComm., 4(3), e261. https://doi.org/10.1002/mco2.261
Zhu J. 2012 . Mammalian cell protein expression for biopharmaceutical production. Biotechnology advances., 30(5): 1158–1170. https://doi.org/10.1016/j.biotechadv.2011.08.022
Zhu, M. M., M. Mollet., R.S. Hubert., Y.S. Kyung., & G.G. Zhang. 2017. Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. Handbook of Industrial Chemistry and Biotechnology., 1639–1669. https://doi.org/10.1007/978-3-319-52287-6_29.